A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma

A. Wang-Gillam,Stacey M. Plambeck-Suess,P. Goedegebuure,P. O. Simon,Jonathan B. Mitchem,John R. Hornick,S. Sorscher,J. Picus,R. Suresh,A. Lockhart,B. Tan,W. Hawkins
DOI: https://doi.org/10.1007/s10637-012-9866-y
2013-06-01
Investigational New Drugs
Abstract:
What problem does this paper attempt to address?